SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

SI-BONE, Inc. (Nasdaq: SIBN), a leading innovator in procedural solutions for compromised bone health, has announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026, in Boston, Massachusetts. The company's management team will engage in a fireside chat at 7:30 a.m. Pacific Time/10:30 a.m. Eastern Time to discuss its advancements and strategies within the healthcare sector. Investors interested in tuning into this significant event can register through the provided link and will also have the opportunity to access a live audio webcast on SI-BONE’s investor relations webpage. Following the conference, the archived version of the session will be available for at least 90 days.

SI-BONE specializes in addressing clinical challenges related to weakened bone structures, particularly in the sacrum, utilizing its advanced knowledge of biomechanics and anatomical innovations. Since its inception in 2009, the company has successfully aided in over 140,000 procedures, reinforcing its reputation with a robust evidence base that includes four randomized controlled trials and more than 180 peer-reviewed publications.

The focus on improving patient outcomes, especially for those with low-density bone, propels SI-BONE to continuously explore new clinical adjacencies. The company aims to expand its impact within the healthcare industry, showcasing both the need for innovative solutions and the effectiveness of its established technologies.

For further details about SI-BONE and its product offerings, including potential risks and benefits, interested parties are encouraged to visit the official website. SI-BONE® is a registered trademark of SI-BONE, Inc., which emphasizes its commitment to advancing healthcare solutions.

As SI-BONE, Inc. (NASDAQ: SIBN) prepares to present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, investors may want to consider several factors before making investment decisions. SI-BONE is positioned as a leader in developing solutions for clinical challenges related to compromised bone, particularly in the spinopelvic region. This niche focus differentiates the company in a crowded orthopedic market.

Investors should closely monitor the insights shared during the fireside chat. The management team's commentary on product development, addressable markets, and recent clinical trials could provide essential guidance on growth prospects. SI-BONE has demonstrated commitment to clinical validation, boasting four randomized controlled trials and over 180 peer-reviewed publications that establish its technologies' efficacy. This strong clinical backing could bode well for future adoption rates among physicians, potentially driving sales growth.

Moreover, with a history of over 140,000 procedures supported, SI-BONE's established footprint in the surgical space enhances its credibility and may reassure investors about its sustainability. Understanding the company’s strategies for tackling new clinical adjacencies will be vital, particularly as the healthcare industry shifts towards personalized and minimally invasive treatment options.

Given current trends favoring innovative technologies in healthcare, SI-BONE's focus on biomechanical design could translate into a competitive advantage. However, investors should also consider market conditions, potential competition, and regulatory landscapes that can impact the company's trajectory.

In summary, while SI-BONE presents an appealing investment case based on its innovative approach and proven track record, careful analysis of the upcoming conference discussion will be imperative for a well-informed investment decision. Listening to the presentation will likely provide further clarity on its future direction and performance expectations.